 "India's Laurus Labs posts 32% profit jump on demand for drug ingredients")
Don't want to miss the best from Business Standard?
BENGALURU (Reuters) - India's Laurus Labs Ltd reported a 32.1% rise in third-quarter profit on Monday, boosted by strong demand in its businesses that make chemicals and other ingredients used in medicines.
The company's consolidated profit rose to 2.03 billion rupees (nearly $25 million) in the three months ended Dec. 31, from 1.54 billion rupees a year earlier.
Revenue at Laurus Labs, which also makes hepatitis C and oncology drugs, rose more than 50% to 15.45 billion rupees.
Laurus Labs said revenue from its Synthesis and active pharmaceutical ingredients (API) businesses, each of which account for more than 40% of total revenue, rose 210% and 49%, respectively, in the latest quarter.
While the Synthesis business manufacturers chemical substances used to make drugs, APIs are key biologically active elements in a drug that help with the desired health effects.
Also Read
Laurus Labs's shares rose as much as 5.3% to 360 rupees on Monday after the results, notching their biggest intraday percentage gain since July.
The stock had declined 30.4% in 2022, compared with an 11.4% fall in the Nifty Pharma index. ($1 = 81.6750 Indian rupees)
(Reporting by Kashish Tandon in Bengaluru; Editing by Savio D'Souza)
Make smarter market moves with The Smart Investor. Daily insights on buzzing stocks and actionable information to guide your investment decisions delivered to your inbox.
(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)
